Clinical trials: PD-1 Inhibitors
HPV-positive Oropharyngeal Squamous Cell Carcinoma
Intranasal WSK-IM05 Vaccine Plus Tislelizumab as Neoadjuvant Therapy for HPV+ OPSCC
This phase I, open-label, single-arm trial uses a "3+3" dose-escalation design to evaluate the safety, tolerability, and preliminary efffcacy of intranasal WSK-IM05 vaccine combined with tislelizumab as neoadjuvant therapy in…
- Trial name
- NCT07565740
- Testing
- WSK-IM05 (4×10^10 vp), WSK-IM05 (8×10^10 vp), WSK-IM05 (1.6x10^11 vp)
- Where
- China
- Volunteers
- 9 people
- Sponsor
- West China Hospital
Advanced Solid Tumor
Combination Therapy of Personalized mRNA-0217 Vaccines and Pembrolizumab in Patients With Advanced Solid Tumors
The main objective of this study was to observe and evaluate the safety and tolerability of mRNA-0217/S001 vaccine encoding personalized tumor neoantigens alone/in combination with Pembrolizumab injection for the treatment of…
- Trial name
- NCT05916248
- Testing
- Personalized neoantigen tumor vaccine, PD-1 inhibitor
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Ruijin Hospital
Head & Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma
Response-adapted Postoperative Radiotherapy In Locally Advanced Head and Neck Cancer
This was a phase II clinical study. Patients with histologically confirmed, resectable, locally advanced head and neck squamous cell carcinoma (HNSCC) without distant metastasis were enrolled.
- Trial name
- NCT07780877
- Testing
- Standard adjuvant radiotherapy based on pathologic findings, De-escalated radiotherapy with a reduced dose, De-escalated radiotherapy with omission of ENI
- Where
- 2 sites in China
- Volunteers
- 85 people
- Sponsor
- Fudan University
Melanoma Stage III, Melanoma Stage IV
Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma
The purpose of this study is to test the effects of anti-PI-1 inhibitor (TSR-042) or anti-PD-1/anti-TIM-3 combination (TSR-042 / TSR-022) in patients with operable melanoma.
- Trial name
- NCT04139902
- Testing
- Dostarlimab (TSR-042) (singly), Dostarlimab (TSR-042) and TSR-022 (combination)
- Where
- 5 sites in United States
- Volunteers
- 58 people
- Sponsor
- Diwakar Davar
Acute T Lymphoblastic Leukemia (T-ALL)
PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALL
This prospective multicenter study evaluates the efficacy and safety of PD-1 inhibitor combined with venetoclax and HAG/CAG chemotherapy in refractory/relapsed T-ALL (R/R T-ALL).
- Trial name
- PD1-VEN-CAG (NCT07541755)
- Testing
- PD-1 Inhibitors
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fujian Medical University Union Hospital
NSCLC Stage IV, Brain Metastases
Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis
Non-small cell lung cancer (NSCLC), the most prevalent form of lung cancer, has a significant risk of brain metastasis (BM). Historically, the median overall survival for advanced NSCLC patients with BM was under six months with…
- Trial name
- NCT06501391
- Testing
- PD-L1/PD-1 inhibitor and chemotherapy, SRT or WBRT
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Fudan University
Pancreatic Adenocarcinoma
9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma
This trial examines how Pancreatic Adenocarcinoma reacts to the addition of 9-ING-41 and retifanlimab to the standard of care chemotherapy treatment, to see if using this combination will help and is able to effect disease…
- Trial name
- RiLEY (NCT05239182)
- Testing
- 9-ING-41, Retifanlimab, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Anwaar Saeed
Lung Cancer, Nonsmall Cell, Renal Cell Carcinoma
Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity
"Risk factors of Immune-ChEckpoint inhibitor MEdiated Liver, gastrointestinal, endocrine and skin Toxicity" (ICEMELT) study is a prospective multicenter cohort study, enrolling patients who are scheduled to receive (1) single…
- Conditions
- Lung Cancer, Nonsmall Cell, Renal Cell Carcinoma, Melanoma, Gastric Cancer
- Trial name
- ICEMELT (NCT04631731)
- Testing
- Blood screening, Tissue screening
- Where
- 2 sites in Australia
- Volunteers
- 200 people
- Sponsor
- Western Sydney Local Health District
Non-Small Cell Lung Cancer
Tumor Growth Rate (TGR) Predicts Clinical Outcomes for Advanced Non-small Cell Lung Cancer Undergoing Immunotherapy.
We hypothesized that TGR could serve as an early predictor of outcomes for aNSCLC patients undergoing immune checkpoint inhibitors (ICIs).
- Trial name
- NCT04722406
- Testing
- This item is not applicable to our observational study.
- Where
- 3 sites in China
- Volunteers
- 350 people
- Sponsor
- Sun Yat-sen University
Advanced Cancer, Ovarian Cancer
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
This is a Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary clinical activity of COM701 as monotherapy and in combination with nivolumab.
- Conditions
- Advanced Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer
- Trial name
- NCT03667716
- Testing
- COM701, COM701 with Opdivo (Nivolumab).
- Where
- 11 sites in United States
- Volunteers
- 121 people
- Sponsor
- Compugen Ltd
Triple Negative Breast Cancer (TNBC)
Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.
Background: Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer with limited treatment options. Research suggests that using High-Intensity Focused Ultrasound (HIFU) to destroy the tumor and/or PD-1…
- Trial name
- NCT07394387
- Testing
- Sintilimab, Abraxane, Carboplatin
- Where
- China
- Volunteers
- 58 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Extensive-stage Small Cell Lung Cancer, Radiotherapy
PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung Cancer
The prognosis of extensive-stage small cell lung cancer is still very poor, even for those who received platinum-based chemotherapy and chest radiotherapy. 2-year survival rate of these patients is only about 10%.
- Conditions
- Extensive-stage Small Cell Lung Cancer, Radiotherapy, Immunotherapy
- Trial name
- PICARES (NCT03971214)
- Testing
- PD-1 inhibitor JS-001
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Chinese Academy of Medical Sciences
Unresectable Hepatocellular Carcinoma
Sequential Transarterial Chemoembolization (TACE), Stereotactic Body Radiation Therapy (SBRT), and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma Treated With Donafenib
This study is a single arm, single center, open label clinical trial. Recruit 34 subjects who meet the inclusion criteria and receive hepatic artery chemoembolization (TACE) and stereotactic body radiotherapy (SBRT) combined with…
- Trial name
- NCT07230314
- Testing
- Donafina, PD-1/PD-L1 inhibitor
- Volunteers
- 34 people
- Sponsor
- Jinling Hospital, China
Recurrent Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression
This is a multicenter, single-arm, phase II clinical study evaluating the efficacy and safety of neoadjuvant finotonlimab (anti-PD-1), cetuximab (anti-EGFR), and docetaxel in patients with resectable recurrent head and neck…
- Trial name
- BRIDGE (NCT07618624)
- Testing
- Finotonlimab, Cetuximab, Docetaxel
- Where
- 9 sites in China
- Volunteers
- 42 people
- Sponsor
- Sun Yat-sen University
PD-1 Inhibitor, G-CSF
PD-1 Inhibitor Plus G-CSF in Recurrent/Metastatic NPC With First-line Treatment Failure
Recurrence and metastasis are the main causes of treatment failure of NPC. Preliminary clinical studies have found that the overall response rate of PD-1 inhibitors in treating ≥2 line R/M NPC is about 25%.
- Trial name
- NCT05222035
- Testing
- Camrelizumab, G-CSF
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Sun Yat-sen University
Non Small Cell Lung Cancer Recurrent
Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)
This is a phase II, single arm, open-label, single-center study to evaluate the efficacy and safety of Toripalimab combined with Chemotherapy and Antiangiogenic Agents in patients with Non-Small Cell Lung Cancer After Failure of…
- Trial name
- NCT05842018
- Testing
- Toripalimab, Anlotinib and Chemotherapy
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Advanced Solid Tumors
Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors
This is a multicenter Phase I/II clinical trial. It aims to evaluate the safety, tolerability, efficacy and pharmacokinetics (PK) of GT201 in patients with advanced solid tumors.
- Trial name
- NCT06144671
- Testing
- GT201, IL-2, PD-1 inhibitor
- Where
- 2 sites in China
- Volunteers
- 78 people
- Sponsor
- Grit Biotechnology
Lung Metastatic Nasopharyngeal Carcinoma
A Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal Carcinoma
This study is a retrospective real-world study. In this study, we plan to collect the clinical data of lung metastatic nasopharyngeal carcinoma patients who received PD-1 inhibitors and chemotherapy combined with or without…
- Trial name
- NCT07062484
- Testing
- Control: gemcitabine, cisplatin, tirelizumab, Experimental: gemcitabine, cisplatin, tirelizumab and radiotherapy
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Malignant Melanoma Stage III
SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma
At present two studies (SWOG S1801 and NADINA) have demonstrated superiority when using neoadjuvant treatment compared to adjuvant treatment only, but no studies have compared PD-1 monotherapy (SWOG 1801 regimen) to the…
- Trial name
- SWE-NEO (NCT06794775)
- Testing
- Nivolumab, Nivolumab + Ipilimumab
- Where
- 3 sites in Sweden
- Volunteers
- 128 people
- Sponsor
- Hildur Helgadottir
Advanced Solid Tumor
A Study of Oncolytic Virus Injection (RT-01) in Combination With PD-1 Inhibitor in Patients With Advanced Solid Tumors
This is a single-arm, open-label, exploratory study to evaluate safety and efficacy of oncolytic virus injection(RT-01) in combination with PD-1 inhibitor (Nivolumab) in patients with advanced solid tumors.
- Trial name
- NCT05228119
- Testing
- Oncolytic Virus Injection(RT-01)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University